Citigroup’s Applied Therapeutics APLT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-163,449
Closed -$16.3K 5933
2025
Q4
$16.3K Buy
163,449
+156,608
+2,289% +$99.5K ﹤0.01% 4919
2025
Q3
$4.14K Sell
6,841
-603
-8% -$284 ﹤0.01% 5284
2025
Q2
$2.32K Sell
7,444
-68,393
-90% -$26.5K ﹤0.01% 5355
2025
Q1
$37.1K Sell
75,837
-4,008
-5% -$2.36K ﹤0.01% 4960
2024
Q4
$68.4K Buy
79,845
+10,178
+15% +$63.8K ﹤0.01% 4988
2024
Q3
$592K Buy
69,667
+48,488
+229% +$286K ﹤0.01% 3622
2024
Q2
$98.9K Sell
21,179
-97,625
-82% -$462K ﹤0.01% 4215
2024
Q1
$808K Sell
118,804
-101,122
-46% -$454K ﹤0.01% 3194
2023
Q4
$737K Buy
219,926
+153,950
+233% +$383K ﹤0.01% 3099
2023
Q3
$164K Buy
+65,976
New +$109K ﹤0.01% 3754
2023
Q2
Sell
-353,138
Closed -$286K 5563
2023
Q1
$286K Buy
353,138
+352,845
+120,425% +$348K ﹤0.01% 3522
2022
Q4
$223 Sell
293
-101,652
-100% -$80.4K ﹤0.01% 5590
2022
Q3
$95K Buy
101,945
+92,868
+1,023% +$111K ﹤0.01% 4113
2022
Q2
$9K Buy
9,077
+6,276
+224% +$10.3K ﹤0.01% 5388
2022
Q1
$6K Sell
2,801
-2,702
-49% -$7.24K ﹤0.01% 5735
2021
Q4
$49K Buy
5,503
+1,821
+49% +$23.9K ﹤0.01% 5068
2021
Q3
$61K Buy
3,682
+585
+19% +$10.1K ﹤0.01% 4634
2021
Q2
$64K Buy
3,097
+1,081
+54% +$20.5K ﹤0.01% 4693
2021
Q1
$38K Sell
2,016
-1,820
-47% -$39.3K ﹤0.01% 4851
2020
Q4
$85K Buy
3,836
+2,047
+114% +$42.6K ﹤0.01% 5655
2020
Q3
$37K Sell
1,789
-139,848
-99% -$3.64M ﹤0.01% 5771
2020
Q2
$5.12M Buy
141,637
+137,774
+3,567% +$5.77M ﹤0.01% 1839
2020
Q1
$126K Buy
3,863
+2,541
+192% +$103K ﹤0.01% 5153
2019
Q4
$36K Buy
1,322
+1,233
+1,385% +$21.1K ﹤0.01% 6577
2019
Q3
$1K Buy
+89
New +$840 ﹤0.01% 7593

Citigroup's APLT Position: Q1 2026 in Review

Citigroup sold out of Applied Therapeutics (APLT) in Q1 2026, closing a stake of 163,449 shares — an estimated $16.3K sold.

Citigroup first reported a position in APLT in Q3 2019 and held it in 25 quarters. The position peaked at $5.12M in Q2 2020. 0 funds tracked by Wall St. Rank hold APLT as of Q1 2026.

  • Citigroup reported no remaining Applied Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Citigroup sold 163,449 Applied Therapeutics shares in Q1 2026, an estimated $16.3K.
  • Citigroup first reported a position in Applied Therapeutics in Q3 2019 and held it in 25 quarters.
  • Citigroup's Applied Therapeutics position peaked at $5.12M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.